

Forward-looking statements



- "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This presentation contains forward-looking statements about the company and its products, including statements relating to components of the company's long-term financial success; the company's traits, commercial products, and collaborations; the company's ability to manage the regulatory processes for its traits and commercial products; the company's anticipated financial results; current and future products under development; additional collaboration agreements; the regulatory process; business and financial plans; and other non-historical facts.
- Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the company's and its partners' ability to develop commercial products incorporating its traits and complete the regulatory review process for such products; continued competition in seed traits and other products; the company's compliance with laws and regulations that impact the company's business, and changes to such laws and regulations; the company's reliance on its collaborators to commercialize products incorporating its seed traits; the company's future capital requirements and ability to satisfy its capital needs; the company's exposure to various contingencies, including those related to intellectual property protection, success of field trials, regulatory compliance, the speed with which regulatory approvals are received, and public acceptance of biotechnology products; developments related to foreign governmental regulations, political climate, currencies and economies; successful operation of the company's joint ventures; fluctuations in commodity prices; the company's ability to obtain a significant portion of the increased value to farmers from products that incorporate its traits; and the effect of weather conditions, natural disasters and accidents on the agriculture business or the company's facilities.
- Further information regarding these and other factors that could affect the company's financial results is included in filings the company makes with the Securities and Exchange Commission from time to time, including the section entitled "Risk Factors" in the company's Annual Report on Form 10-K for the year ended December 31, 2018. These documents are or will be available on the SEC Filings section of the Investor Relations pages of the company's website at www.arcadiabio.com. All information provided in this presentation and in the attachments is as of the date hereof, and Arcadia Biosciences, Inc. undertakes no duty to update this information.

Arcadia transforms into a health and nutrition ingredients company



- Launched GoodWheat[™] portfolio of specialty wheats with advanced nutritional profiles
- Achieved key milestones in amylose levels for Resistant Starch wheat lines



- Added Reduced Gluten to the GoodWheat line of products
- Built partnerships with key players in the wheat value chain
- Collaborating with Ardent Mills to develop and commercialize wheat innovations
- Received US patent for Extended Shelf Life Wheat
- Demonstrated agronomics of GoodWheat in production trials in multiple locations
- Completed formulation testing of GoodWheat ingredients in various food products with major research lab



Arcadia's crop productivity traits continued technical and commercial progress



HB4 Drought Tolerant Soybeans




- 2018 field trials coincided with drought conditions, demonstrating benefits of trait
- HB4 and herbicide tolerant trait stack approved in Argentina
- Third season of breeding trials underway

Extended Shelf Life Tomato

 Key milestone achieved, partner Bioseed in India expects to commercialize in 2019

Abiotic Stress Traits in Rice and Cotton

- NEWEST* Rice shows double digit yield increases in field trials with the African Agricultural Technology Foundation
- Nitrogen Use Efficient Rice and Cotton field trials progress in India



^{*} Nitrogen Use Efficiency, Water Use Efficiency, Salinity Tolerance



Now that it's legal, cannabis is set to undergo its own "Green Revolution"



1960's



Norman Borlaug's

Green Revolution

Maximized the genetic potential of seeds by using technology including irrigation, breeding, mechanization, and chemistry like fertilizers, pesticides

Impact

- Improved global cereal yields 2.5X
- Saved 35-65% in food costs
- Prevented 11-13% caloric loss

1990's



Modern Seed & Trait
Development

Maximized the genetic potential of seeds using biotechnology including microbiology, genetics, biochemistry, chemistry, nutrition and food technology, engineering, electronics, IT & data

Impact

- 213M more tons soy, 405M more tons corn on same land area
- Gross farm incomes increased \$186.1 B

Today




Modern Germplasm & Trait Development in Cannabis

Using the best science, Arcadia Specialty Genomics will bring modern ag practices to cannabis

Cannabis yield gains are expected as the crop benefits from modern innovation







* Includes corn, soybeans, rice and wheat

Sources: OECD

World Bank

The Atlantic, January 1997

Leveraging Arcadia's expertise in plant science to improve cannabis plant content, quality, climate resiliency and yield





- Cannabis lags behind other crops in advanced breeding to improve cultivation and consistency
- Suboptimal genetics threaten the scalability and long-term viability of the industry
- Arcadia's expertise in plant innovation offers:
 - Novel, traceable cannabis varieties that improve the crop's productivity for cultivators
 - Quality traits to improve its functional value as a consumable ingredient
- With the legalization of hemp under the 2018 Farm Bill, the USDA is only now beginning to develop national guidelines
- Arcadia Specialty Genomics will immediately begin growing industrial hemp as part of a pilot program in Hawaii

Arcadia's trait-to-CPG model and proven success in other crops can be applied in cannabis



| | Seed & Trait Development | | | | Ingredient Production | | | | Branded Product Sales | | |
|--|--------------------------|----------------------|-----------------------|------------------------------|-----------------------|--------------|----------------------|----------|-----------------------|------------------------|-----------------|
| | Build trait | Execute in germplasm | Protect via IP/PVP | Enable practice (regulatory) | Grow | Harvest | ldentity preserve | Process | Brand | Model in food & health | Sell to CPGs |
| GLA Safflower | \checkmark | \checkmark | \checkmark | | \checkmark | \checkmark | V | • | \checkmark | • | \checkmark |
| Increased gamma-linolenic acid (GLA) concentration from <1% to 65% in safflower crop Highest plant-based source available – evening primrose and borage have 10%-22% | | | | | | | | | | | |
| GoodWheat | | ✓ • | | | | | | ♦ | | | (2019) |
| Increased amylose content to 94% – highest available in wheat Reduced allergenic glutens by 70% | | | | | | | | | | | |

☑ Delivered by Arcadia

Delivered by managed partners

Key financial results



| | | Fourth Qu | uarter | | Twelve Months | | | | |
|---|-------------------------|-----------|---------|---------|-------------------------|-----------|---------|--------|--|
| | Favorable/(Unfavorable) | | | | Favorable/(Unfavorable) | | | | |
| | 2018 | 2017 | \$ | % | 2018 | 2017 | \$ | % | |
| Total revenues | 444 | 1,428 | (984) | (69%) | 1,464 | 4,026 | (2,562) | (64%) | |
| Cost of product revenues | 230 | 20 | (210) | (1050%) | 661 | 283 | (378) | (134%) | |
| R&D expense | 1,545 | 2,167 | 622 | 29% | 6,069 | 7,407 | 1,338 | 18% | |
| SG&A expense | 3,023 | 2,241 | (782) | (35%) | 11,604 | 10,651 | (953) | (9%) | |
| Total operating expenses | 4,798 | 4,428 | (370) | (8%) | 18,334 | 18,341 | 7 | 0% | |
| Loss from operations | (4,354) | (3,000) | (1,354) | (45%) | (16,870) | (14,315) | (2,555) | (18%) | |
| Other income and expense* | 3,708 | 40 | 3, 668 | 9,170% | 3,390 | (1,392) | 4,782 | 344% | |
| Net loss attributable to common stockholders | (646) | (2,960) | 2,314 | 78% | (13,480) | (15,707) | 2,227 | 14% | |
| Net loss per share attributable to common stockholders | \$(0.14) | \$(1.39) | | | \$(3.58) | \$(7.28) | | | |
| Basic and diluted shares outstanding (weighted average) | 4,774,919 | 2,134,154 | | | 3,766,419 | 2,156,201 | | | |

^{*} Includes interest expense, tax provision, other income, loss and change in FV of liabilities, loss on extinguishment of debt, and offering costs

3/27/2019 - © Arcadia Biosciences, Inc.

